Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 181 to 195 of 456 results for chronic pain

  1. Irritable bowel syndrome in adults (QS114)

    This quality standard covers diagnosing and managing irritable bowel syndrome in adults. It describes high-quality care in priority areas for improvement.

  2. Xeomin (botulinum neurotoxin type A) for treating chronic sialorrhoea (TA605)

    Evidence-based recommendations on Xeomin (botulinum neurotoxin type A) for treating chronic sialorrhoea (excessive salivation and drooling) caused by neurological conditions in adults.

  3. Medicines associated with dependence or withdrawal symptoms: safe prescribing and withdrawal management for adults (NG215)

    This guideline covers general principles for prescribing and managing withdrawal from opioids, benzodiazepines, gabapentinoids, Z-drugs and antidepressants in primary and secondary care.

  4. The Versajet II hydrosurgery system for surgical debridement of acute and chronic wounds and burns (MIB1)

    NICE has developed a Medtech Innovation Briefing (MIB) on the Versajet II hydrosurgery system

  5. Photodynamic therapy for early-stage oesophageal cancer (HTG128)

    Evidence-based recommendations on photodynamic therapy for early-stage oesophageal cancer. This involves injecting a photosensitising agent into the tumour which is then activated by a light to destroy the tumour cells.

  6. High-intensity focused ultrasound for glaucoma (HTG527)

    Evidence-based recommendations on high-intensity focused ultrasound for glaucoma in adults. This involves using high-intensity ultrasound to destroy a small amount of the tissue that makes fluid in the eye.

  7. Trabeculectomy with a biodegradable collagen matrix implant for glaucoma (HTG656)

    Evidence-based recommendations on trabeculectomy with a biodegradable collagen matrix implant for glaucoma. This involves cutting a small flap in the white of the eye and putting a patch over the flap to help healing and prevent scarring. Fluid slowly drains out of the flap and the patch dissolves over time. The aim is to reduce pressure in the eye and slow or stop damage to sight.

  8. Adalimumab for treating moderate to severe hidradenitis suppurativa (TA392)

    Evidence-based recommendations on adalimumab (Humira) for treating active moderate to severe hidradenitis suppurativa in adults whose disease has not responded to conventional systemic therapy.

  9. Varicose veins in the legs (QS67)

    This quality standard covers diagnosing and managing varicose veins in the legs of adults (aged 18 and over). It includes referral for specialist assessment and treatment options. It describes high-quality care in priority areas for improvement.

  10. Rehabilitation after traumatic injury (NG211)

    This guideline covers complex rehabilitation needs after traumatic injury, including assessment and goal setting, rehabilitation plans and programmes, physical, psychological and cognitive rehabilitation, rehabilitation for specific injuries, coordination of rehabilitation in hospital, at discharge and in the community, and commissioning and organising rehabilitation services.

  11. Repetitive short-pulse transscleral cyclophotocoagulation for glaucoma (HTG576)

    Evidence-based recommendations on short-pulse transscleral cyclophotocoagulation for glaucoma. This involves using repeated short pulses of laser energy to destroy some of the cells in the eye that produce fluid.

  12. Fremanezumab for preventing migraine (TA764)

    Evidence-based recommendations on fremanezumab (Ajovy) for preventing migraine in adults.

  13. LQD Spray for treating acute and chronic wounds (MIB202)

    NICE has developed a medtech innovation briefing (MIB) on LQD Spray for treating acute and chronic wounds .